Sentences with phrase «improve immunotherapy»
The intent of the effort is to build off the identified immunologic factors that may be modulated to improve immunotherapy for CRC patients, with the goal that the biomarkers and treatment strategies identified in the manuscript will become part of the routine management of colorectal cancer (CRC).
http://cancerresearch.org/
These clinical trials have been, and continue to be, important for the advancement of improved immunotherapies for all patients, including children.
Bradley Wayne Blaser, M.D., Ph.D., of Boston Children's Hospital, is the studying the factors that control blood cell development, with the goal of improving immunotherapies for patients with leukemia.
Not exact matches
That said, there is a growing sense among many cancer experts that immunotherapy could improve by leaps and bounds if the right mysteries are unlocked.
«While we are disappointed CheckMate - 026 did not meet its primary endpoint in this broad patient population, we remain committed to improving patient outcomes through our comprehensive development program, including the ongoing Phase III CheckMate - 227 study exploring the potential of the combination of Opdivo plus [our other cancer immunotherapy] Yervoy for PD - L1 positive patients, and Opdivo plus Yervoy, or Opdivo plus chemotherapy in PD - L1 negative patients,» he added.
April 16 Merck & Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly - diagnosed patients with advanced non-small cell lung cancer in a highly - anticipated study that appears to cement the company's lead in the most lucrative oncology market.
We have a lot to learn about improving therapeutic effectiveness, Chan says: «Immunotherapy isn't magic.
Much current research in immuno - oncology focuses on improving these treatments, for example, by finding new immunotherapy targets and identifying biomarkers that predict a patient's response.
«If successful,» Zhou said, «all these efforts would remarkably improve the current cancer immunotherapies by personalizing the treatment to exactly where and when it is needed, while reducing side effects.»
«Immunotherapy drug improves survival for common form of lung cancer.»
Immunotherapy doubles overall survival and improves quality of life, with fewer side effects, in a treatment - resistant and rapidly progressing form of head and neck carcinoma, reports a large, randomized international trial co-led by investigators at the University of Pittsburgh Cancer Institute (UPCI).
«Immunotherapy with live bacterium improves response rate in malignant pleural mesothelioma.»
«Our research sheds light on the mechanism of this impairment, pointing us in the direction of new strategies for improving the response to immunotherapy.»
«Immunotherapy is considered one of the most important breakthroughs in cancer care in decades, but there is more research needed to improve its success in the clinic.
Today, new immunotherapy drugs have shown great promise in melanoma, but many patients fail to respond, underscoring the need to further improve the drugs» abilities.
The ultimate goal of Dr Janji's research team is to provide the proof of concept that targeting autophagy could improve the efficacy of current immunotherapies, notably those based on immune checkpoint blockades.
«First - line immunotherapy treatment can improve survival for subset of lung cancer patients: Results of phase III global clinical trial show that 75 percent of stage IV lung cancer patients with both complex tumor mutations and PDL - 1 positive status respond to nivolumab.»
«Immunotherapy drug nearly eliminates severe acute graft - versus - host disease: Drug used to treat rheumatoid arthritis improves survival after hematopoietic stem cell transplant.»
«The microbiome appears to shape a patient's response to cancer immunotherapy, which opens potential pathways to use it to assess a patient's fitness for immunotherapy and to manipulate it to improve treatment,» said Wargo, who is also co-leader of the Melanoma Moon Shot ™, part of MD Anderson's Moon Shots Program ™ to reduce cancer deaths by accelerating development of therapies from scientific discoveries.
Researchers from the University of Missouri School of Medicine have identified a molecular mechanism that operates in memory T cells that could be manipulated to produce and maintain more memory T cells in the body, a finding that could improve vaccinations and cancer immunotherapies.
Now, researchers from the University of Missouri School of Medicine have identified a molecular mechanism that operates in memory T cells that could be manipulated to produce and maintain more memory T cells in the body, a finding that could improve vaccinations and cancer immunotherapies.
Carretero and his colleagues therefore investigated whether the outcomes of these immunotherapies might be improved by adding eosinophils.
And while targeted treatments and immunotherapies have dramatically improved the prognosis for many patients with sun - associated melanomas, these treatments are ineffective in the mucosal form of the disease.
Although immunotherapy treatments that emerged in the last few years have vastly improved survival rates over previous chemotherapy treatments, metastatic MCC still has a high potential to be fatal, he says, making early detection especially vital.
«It is clear from these two studies that we still have a long way to go, but proper selection of patients, improved techniques in radiotherapy and new immunotherapy treatments will help us to fight this terrible disease.»
Chair of Trustees, Harry Cotterell OBE, said: «These are exciting results and support our hope that immunotherapy will in future become a generally accepted treatment for a wide range of cancers, improving both survival rates and quality of life.»
These results, published in Nature Communications, have the potential to improve current cancer immunotherapy strategies, especially in relation to the prevention of metastasis (dissemination of the tumor to organs distant from the site of origin).
«Key to improved cancer immunotherapy: Study demonstrates that tissue - resident and circulating memory T cells cooperate in anti-tumor immunity.»
«Combination immunotherapy improves survival in mouse models of mesothelioma: Mass..
«The most exciting finding was that TAM reprogramming greatly improved the efficacy of immunotherapy,» says Michele De Palma.
«As we identify which bacteria have a similar effect in humans, it should be possible to develop probiotic supplements that specifically improve efficacy of immunotherapies,» he says.
In addition to Amgen's work to improve cancer patient treatment through science - based innovation, CRI will also recognize the company's commitment to the broader scientific and patient communities, both through its support of CRI's Cancer Immunotherapy Month education and awareness initiative, and for its support of the CRI - CIMT - EATI - AACR International Cancer Immunotherapy Conference, a joint program of four cancer research organizations that convenes world - leading scientists to discuss the latest in cancer immunology and immunotherImmunotherapy Month education and awareness initiative, and for its support of the CRI - CIMT - EATI - AACR International Cancer Immunotherapy Conference, a joint program of four cancer research organizations that convenes world - leading scientists to discuss the latest in cancer immunology and immunotherImmunotherapy Conference, a joint program of four cancer research organizations that convenes world - leading scientists to discuss the latest in cancer immunology and immunotherapyimmunotherapy research.
Seres is developing SER - 401, a preclinical stage oral microbiome therapy comprising a consortium of live bacteria to improve the efficacy and safety of immunotherapy.
CLIP Grants provide funding for qualified scientists who are working to explore clinically relevant questions aimed at improving the effectiveness of cancer immunotherapies.
To meet this end, CCIR members take advantage of resources offered by MD Anderson, including the CCSG Shared Resources, Immune Monitoring Core Laboratory and GMP Cell Facility, allowing them to follow the «bench - to - beside» approach to develop and improve cancer immunotherapy in the form of cellular therapy, a vaccine or targeting antibody, either alone or in combination with conventional therapies or newly developed therapies.
We expect that the CRI iAtlas will help to accelerate discovery and improve patient outcomes by providing researchers greater access to genomics data to better understand the immunological characteristics of the tumor microenvironment and its potential impact on patient responses to immunotherapy,» said Jill O'Donnell - Tormey, Ph.D., CEO and director of scientific affairs at CRI.
Our objective is to use our microbiome therapeutic approach to improve the efficacy of immunotherapy in patients with life - threatening cancers.»
Although this benefit has not been seen in all patients treated with immunotherapy, one of the goals of the CCIR is to improve our understanding of the immune system, especially in the context of the tumor immune microenvironment, in order to modulate immunity to optimally enhance patient outcome.
Daniel Haber, director of the Massachusetts General Cancer Center, remembers the group talking about CRISPR gene editing, artificial intelligence to improve diagnosis and treatment plans, and immunotherapy techniques that incite the immune system to fight tumors.
The Center for Cancer Immunology Research (CCIR) addresses immunology - based approaches to the treatment of cancer and has emerged as a one - of - a-kind cancer immunology research program that allows laboratory immunologists to work with clinical oncologists to develop new or improved forms of cancer immunotherapy that activate and instruct our immune system to eliminate cancer and prevent its recurrence.
There are options such as immunotherapy that can substantially improve quality of life and potentially cure the cancer.
Alterations to DDR genes were associated with improved outcomes in patients with metastatic urothelial carcinoma who were treated with immunotherapy.
Targeting negative regulators downstream of the TCR represents a novel strategy to improve cancer immunotherapy.
Upcoming interventional trials will examine immunotherapy in combination with other novel agents in an effort to improve both short - and long - term outcomes for patients.
Although recent advances in immunotherapy and CAR - T cells have rapidly improved cancer therapy and remission rates, there is still no «silver bullet» for cancer.
The researchers were curious about whether lowering stress with beta blockers would improve outcomes in patients treated with immunotherapies.
Dr. Joseph Drabick, professor of medicine, said the results suggest that reducing physiological stress with beta blockers can help improve the effectiveness of immunotherapy and survival for melanoma patients.
Combining CAR - T immunotherapy and CRISPR / Cas9 may improve our chances of success for treating cancer and other genetic diseases in several ways.
However, it could dramatically improve the efficacy of current immunotherapy drugs, which now have a 20 to 50 percent success rate.
After having their tumors removed and receiving immunotherapy, most of the women improved or recovered.